Treatment of acute, high-risk pulmonary embolism (PE) remains controversial among specialists. Systemic thrombolysis using rtPA is the current standard, but other mechanical and surgical options are emerging. Some believe rtPA is outdated due to technological advances, while others argue its efficacy and support its use. Alternatives like catheter-directed therapies and ECMO offer promise but also come with challenges. Studies, like FLAME, have shown positive outcomes with mechanical treatments, but questions about long-term effectiveness and complications remain. Ongoing trials, like PEITHO-3 and FLARE, aim to provide more clarity on the most effective and safe treatments for high-risk PE.
Source link
Debate Over Best Treatment for High-Risk PE at ERS 2024
